Physician profile
Stanley E Peters
NPI 1013906304
$799.18
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.96 · 2020: $155 · 2021: $286 · 2022: $267.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $553.31 | 2019-2022 | |
| Abbvie INC. | $57.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.97 | 2021 | |
| Genzyme Corporation | $32.81 | 2022 | |
| Arbor Pharmaceuticals, INC. | $26.46 | 2019 | |
| Stryker Corporation | $21.97 | 2021 | |
| Intersect Ent, INC. | $16.40 | 2019 | |
| Medtronic, INC. | $15.83 | 2021 | |
| Allergan, INC. | $14.88 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.